Table 3. The frequency distribution of CYP2C19 genotypes, alleles and clopidogrel metabolic types in different sexes
From: Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled
| Â | Number | Male(n=343) | Female(n=206) | X2 | P | |
|---|---|---|---|---|---|---|
Genotype | CYP2C19*1/*1 | 191 | 117 (61.26) | 74 (38.74) | 9.464 | 0.092 |
CYP2C19*1/*2 | 233 | 159 (68.24) | 74 (31.76) | |||
CYP2C19*1/*3 | 30 | 18 (60.0) | 12 (40.0) | |||
CYP2C19*2/*2 | 65 | 34 (52.31) | 31 (47.69) | |||
CYP2C19*2/*3 | 29 | 15 (51.72) | 14 (48.28) | |||
CYP2C19*3/*3 | 1 | 0 | 1(100.0) | |||
Allele | CYP2C19*1 | 645 | 411(63.72) | 234 (36.28) | 2.345 | 0.310 |
CYP2C19*2 | 392 | 242(61.73) | 150 (38.27) | |||
CYP2C19*3 | 61 | 33 (54.10) | 28(45.90) | |||
Metabolic types | extensive metabolizers | 191 | 117 (61.26) | 74 (38.74) | 7.544 | 0.023 |
intermediate metabolizers | 263 | 177 (67.30) | 86 (32.70) | |||
poor metabolizers | 95 | 49 (51.58) | 46 (48.42) | |||